Navigation Links
NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
Date:2/17/2011

tures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenue, loss, gross margin and Adjusted EBITDA numbers, expectations with respect to market momentum of further product innovation, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our major customers, including DaVita Inc., and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended September 30, 2010.

In addition, the statements in this press release represent NxStage's expectations and b
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NxStage® to Report Fourth Quarter and Full Year 2010 Financial Results
2. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
3. First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
4. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
5. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. Masimo Reports Fourth Quarter and Full Year 2010 Financial Results; Provides 2011 Guidance
8. Allscripts Reports Fourth Quarter Results
9. Mesa Labs Reports 44% Increase in Third Quarter Revenues
10. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
11. Cambrex Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , August 27, 2015 ... Persistence Market Research titled "Global Market Study on ... Growth by 2021", the urinary catheters market is expected to ... of 2015. It is anticipated to expand at ... reach US$1,755.0 Mn by 2021. View ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... and Chief Executive Officer, will present at the Cowen ... Boston Marriott Copley Place.  The presentation is scheduled for ...
... 2011 HeartWare International, Inc. (Nasdaq: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... a.m. Eastern Time on Tuesday, March 15, 2011. The ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:8/27/2015)... ... 27, 2015 , ... StayWell, a leading provider of patient ... ICD-10 ready and available to all clients. All Krames Patient Education content has ... more targeted and return a more comprehensive data set of content than the ...
(Date:8/27/2015)... , ... August 27, 2015 , ... In addition to ... University now offers a third doctoral program at its main campus in Reading: Doctor ... terminal degree program designed to prepare advanced practice nurses for the highest level of ...
(Date:8/27/2015)... ... August 27, 2015 , ... Market ... market research promotion on the Internet. MarketPublishers.com is now authorised to distribute ... the partnership agreement, Natalie Aster, Assistant Manager at Partners Department, noted: "Black ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Sunbelt® Bakery, ... high fructose corn syrup, is changing the expectation of how protein bars should taste ... indulgent taste unlike any other protein bar on the market today. , The ...
(Date:8/27/2015)... La Mirada, Ca (PRWEB) , ... August 27, ... ... throughout Southern California including Los Angeles, Riverside, San Bernardino, and Orange ... executive employees, Healthpointe’s executive physical exams are offered annually at all of its ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Healthpointe Now Offering Executive Physicals 2
... Using small molecules (purine analogs) scientists ... lung cancer, a common obstacle to successful, ... - HTDS www.htdsmedical.com (HTDS) - The issuer,s ... brings attention to its Mindup Bioresearch cancer project working ...
... At a Los Angeles gala, family and friends ... in paying tribute to women,s health advocate and fitness ... Beverly Wilshire Hotel where friends toasted LaLanne for being ... in shape and lead healthier lifestyles. , (Photo: ...
... French . , Winnipeg (October 14, 2009) The ... (CIHR) today announced support for five new research projects ... virus. "Canada is a global leader in ... on a safe and effective H1N1 vaccine," said Health Minister ...
... tumor growth without harmful therapies, study suggests , WEDNESDAY, ... scientists closer to their goal of treating pancreatic cancer ... The researchers, who were scheduled to report their findings ... 11-15 in Chicago, have created a bioengineered "construct" that ...
... GLENDALE, Calif., Oct. 14 Although some parents may ... www.LakesideCommunityHealthcare.com , one of Southern California,s ... about both the safety of and access to the ... www.LakesideFluInfo.com to give patients direct access ...
... Oct. 14 Cardium Therapeutics (NYSE Amex: CXM ... 2b clinical trial of Excellarate(TM) for the potential treatment ... on the Company,s Gene Activated Matrix (GAM) technology platform. ... product candidate (GAM501, which is a combination of Ad5PDGF-B ...
Cached Medicine News:Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 2Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 3Health News:Slavica Bio Chem MindUp Cancer Project (HTDS) Research Led To The Identification Of Genes Associated With Lung Cancer Promotion And Progression 4Health News:Jack LaLanne Celebrated as Fitness Icon at Star-Studded Birthday Bash 2Health News:Government of Canada supports scientific research to deepen knowledge of H1N1 flu virus 2Health News:Stem Cells Being Tested to Fight Pancreatic Cancer 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14
Cold light source single outlet....
Cold light source single outlet....
Cold light source single outlet....
Cold light source triple outlet....
Medicine Products: